Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Proposes Part D Protected Drug Criteria, Drops Antidepressants And Immunosuppressants

This article was originally published in The Pink Sheet Daily

Executive Summary

A proposed Medicare rule says under new criteria CMS has developed, antidepressants and immunosuppressants will no longer be protected classes in plan formularies, but antineoplastics, antiretrovirals and anticonvulsants will remain. Antipsychotics will also be protected through 2015 as CMS continues to evaluate the class.

You may also be interested in...



Medicare Part D Protected Classes Targeted in Last-Minute Payment Demo Update

If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.

CMS Proposal On Part D May Address Drug Costs, But Will It Target Prices?

Upcoming proposed rule on Medicare Part D and Medicare Advantage prompts speculation about whether CMS is planning new measures to control spending on prescription drugs.

Narrowing Part D Protected Classes Won’t Be Proposed Again – Tavenner

CMS Administrator Tavenner provides public assurances that the agency will not reintroduce a proposal to remove antidepressants, antipsychotics and immunosuppressants from protected status in the Medicare Part D program.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS076467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel